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etection of Subclinical
abry Disease in Patients
resenting With Hypertrophic
ardiomyopathy*
ichael J. Ackerman, MD, PHD, FACC,
ndrew P. Landstrom, BS
ochester, Minnesota
n the post-genomic era of science and medicine, genetic
esting to determine subclinical disease, which escapes
onventional clinical diagnosis, is being increasingly used. In
ddition, clinical genetic testing plays an important role in
he diagnosis of pleomorphic disorders that might not only
resent subclinically but also with variable symptomology.
See page 2399
Anderson-Fabry disease (AFD), an inborn error of me-
abolism, affects an estimated 1 in 50,000 men and is due to
oss-of-function mutations in GLA-encoded lysosomal
lpha-galactosidase A (-gal), an enzyme responsible for
reaking down fatty substances in the body called globo-
riaosylceramides (GL-3) (1,2). The resulting accumulation
f GL-3 in the vascular endothelial lysosomes causes a
ighly variable clinical presentation that might manifest as
croparesthesias, angiokeratoma, corneal and lenticular
pacities, and anhidrosis (3). In addition, the gradual
ccumulation of GL-3 in the walls of the blood vessels and
issues such as the heart, kidneys, and brain causes progres-
ive tissue damage and potentially life-threatening prob-
ems. Unabated, this disease results in severe microvascular
ysfunction and early death. Importantly, although AFD is
ften a systemic disorder, cardiac involvement can occur
xclusively in the presence of specific GLA mutations (4,5).
urthermore, in this AFD variant, the resulting myocardial
ypertrophy and mitral valve thickening can mimic hyper-
rophic cardiomyopathy (HCM) (6).
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
ollege of Cardiology.
From the Departments of Medicine, Pediatrics, and Molecular Pharmacology ands
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tric Cardiology, Mayo Clinic, Rochester, Minnesota.Localizing to the long arm of chromosome X (Xq22),
LA-opathies are far more expressive in men than women.
en with 1% residual -gal activity generally manifest
FD, whereas men with 5% to 15% residual levels of -gal
ctivity are more likely to display a cardiac-only phenotype
hat, to the eyes of an echocardiographer, looks for all the
orld to be indistinguishable from classical HCM. Depend-
ng on the nature of the X chromosome inactivation in
omen (lyonization), women might variably express the
pectrum of AFD as well (7,8). Furthermore, as many as 3%
f men with unexplained left ventricular hypertrophy
LVH) in 1 study (6) and 6.3% of men with late-onset
CM in another (7), had low -gal enzyme activity.
onversely, among a cohort of women hosting heterozy-
ous mutations in GLA, 55.6% of women 38 years of age
emonstrated LVH, whereas all women over 45 years had
ignificant LVH (9).
Unlike sarcomeric/myofilament HCM that lacks gene-
pecific therapy, AFD and GLA-mediated HCM are po-
entially very treatable, given the availability of recombinant
-gal enzyme replacement therapy since 2001 (10). Early
etection of at-risk individuals is vital to ensure proper
urveillance of disease expression and gene-specific pharma-
otherapy (i.e., enzyme replacement therapy) (10,11).
abry Disease Within an HCM Cohort
n this issue of the Journal, Monserrat et al. (12) provide an
legant study demonstrating that, within a Spanish cohort
f 508 unrelated patients with clinically diagnosed HCM,
pproximately 3% (6 of 328 men, 9 of 180 women) had
educed -gal enzymatic activity ranging from 0% to 30% in
en and 0% to 50% in women. Genetic analysis of this
ubset of 15 patients with reduced -gal enzymatic activity
evealed 5 (33%) having GLA mutations associated with
FD. This proportion of mutation-positive cases within
FD is similar to the 12 (29.2%) mutation-positive cases in
1 neonates with reduced -gal activity observed previously
13). When the residual levels of -gal enzymatic activity were
20%, the probability of detecting a GLA mutation ap-
roached 100%. Furthermore, the highest residual level of
-gal for which a positive mutation was nonetheless detected
as 25%.
None of the mutations previously seen in patients with
ardiac-only AFD or isolated GLA-HCM were detected
ere (6). Instead, 3 of the 4 GLA mutations (L89P, A143T,
nd E358del) discovered by Montserrat et al. (12) have been
ssociated previously with classical or delayed-onset AFD.
mportantly, although neither the L89P- nor A143T-
ositive index case had a personal history to suggest AFD,
etrospective sleuthing revealed clues in the family that
ould have prompted suspicion as to the presence of a
eritable multiorgan syndrome. For example, the index case
ith L89P-GLA had a nephew who developed renal failure
t 35 years of age, without a specific diagnosis, after
uffering from acroparesthesias as a child. He went on to
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December 18/25, 2007:2404–5 Editorial Commentevelop concentric LVH and suffered from multiple cerebral
nfarctions. Furthermore, the index case’s sister died after
ialysis of renal failure at 24 years.
In addition, the E358del-GLA–positive subject did have
ymptoms compatible with AFD, including a history of hypo-
idrosis and mild renal failure. Only the novel missense
utation, S238N, was detected in 2 patients with seemingly
solated GLA-HCM or cardiac only, atypical AFD. Exclusion
f these 3 patients that had a compelling personal/family
istory consistent with AFD, albeit in retrospect, would
uggest that the frequency of GLA-HCM might be approxi-
ately 0.4% (2 of 505) with clinically/echocardiographically
iagnosed HCM.
creening for Fabry Disease
n Patients Presenting With LVH
iven this low frequency, it seems debatable as to whether
iochemical testing to determine -gal activity should be a
tandard part of the clinical evaluation of HCM. To be sure,
he identification of a GLA-positive subject will permit: 1)
stablishing the correct diagnosis—cardiac AFD or GLA-
ediated HCM rather than sarcomeric HCM; 2) proper
urveillance for disease/organ expression; 3) proper classifi-
ation of at-risk relatives; 4) proper counseling of transmis-
ion risk, including affected men (having 0% transmission
isk to men, 100% transmission risk to female offspring,
hereas affected women have 50% transmission risk to their
hildren, with men being affected and women being “carri-
rs”); and 5) treatment with genotype-specific enzyme
eplacement therapy. Indeed, failure to distinguish cardiac
ypertrophy secondary to AFD from “classical” HCM
i.e., sarcomeric/myofilament-HCM) can cause the pa-
ient to be deprived of potentially life-saving enzyme
eplacement therapy.
At first blush, this tandem biochemical screen and sub-
equent deoxyribonucleic acid sequencing of GLA seems a
ost prudent recommendation. In the study by Monserrat
t al. (12), precisely because of the detection of reduced
-gal activity and subsequent genetic confirmation of a GLA
efect in the 5 index cases, 14 GLA mutation-positive
elatives—6 of whom demonstrated no clinical manifesta-
ions of AFD—were exposed. Thus, at-risk individuals were
iscovered pre-clinically, which enabled initiation of careful
urveillance for the early detection of organ(s) involvement
nd treatment with enzyme-replacement therapy.
Despite this obvious clinical benefit, formal cost-effective
nalyses have not been performed for routine biochemical
creening of -gal activity in the evaluation of HCM.
iochemical assays to determine -galactosidase enzymatic
ctivity cost approximately $250. If done as clinical practice
n the U.S., the cost to screen the 508 patients in this study
ould exceed $125,000. For the 3% that exceeded the
re-specified cut-off value prompting GLA genetic testing,nother $10,000 would be required for the GLA genetic test
$700/test in the U.S.). Given the thresholds used here, only
ne-third of the patients directed to the second tier of AFD
esting will have a positive genetic test. Thus, the cost to
stablish either clinically unrecognized AFD or GLA-
CM status for the 5 index cases was $135,000. The
otential cost of screening increases when one considers that
he time-honored and relatively inexpensive past medical
istory and family history perhaps should have prompted a
argeted suspicion of AFD for 3 of the 5 positive cases. If
hese back-of-the-napkin calculations are validated by for-
al cost-effective analyses, then a recommendation for
niversal -gal screening in the evaluation of hypertrophic
ardiomyopathy might fall on deaf ears.
eprint requests and correspondence: Dr. Michael J. Ackerman,
indland Smith Rice Sudden Death Genomics Laboratory,
uggenheim 501, Mayo Clinic, Rochester, Minnesota 55905.
-mail: ackerman.michael@mayo.edu.
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